ABSTRACT
INTRODUCTION
Impaired placentation and/or placental dysfunction, reflected in an increased pulsatility index (PI) in the uterine arteries (UtAs), reduced serum placental growth factor (PlGF) and increased soluble fms-like tyrosine kinase-1 (sFlt-1), are associated with the subsequent development of pre-eclampsia (PE) and the birth of a small-forgestational-age (SGA) neonate 1 -3 . In the 1980s, analysis of fetal blood obtained by cordocentesis demonstrated that some SGA fetuses are hypoxemic and acidemic and have a metabolic profile compatible with intrauterine starvation 4 -6 . In SGA fetuses, hypoxemia was found to be associated with increased impedance to flow in the UtA and umbilical arteries (UAs) and reduced impedance in the fetal middle cerebral artery (MCA) 7 -9 . It was recognized that the majority of fetuses that are growth restricted due to uteroplacental insufficiency may not actually be SGA 10 and it was speculated that if the biomarkers of fetal hypoxia are as useful in identifying affected fetuses that are not small as they are for identifying SGA fetuses, the biomarkers may replace measurement of fetal size for the antenatal prediction of fetal asphyxia 7 . A large screening study at 30-34 weeks' gestation reported that biomarkers of impaired placentation/placental dysfunction and fetal hypoxemia are useful in the prediction of PE and the birth of SGA neonates 11 . However, the biomarkers provide poor or no prediction of adverse events in labor or after birth, including Cesarean section for fetal distress, low cord blood pH, low Apgar score or neonatal unit (NNU) admission for cases other than those with PE and/or SGA 11 . Possible explanations for poor performance of screening at 30-34 weeks in prediction of adverse events in labor or after birth are, first, the premise that non-SGA starved fetuses are as hypoxic as SGA starved fetuses is not true 12 , second, the outcome measures are primarily the consequence of problems which start in labor and therefore cannot be predicted using markers of chronic fetoplacental hypoxia, and third, assessment at 30-34 weeks is too remote from events in labor and that assessment at 35-37 weeks may improve the screening performance for labor-related adverse outcomes.
The objective of this screening study was to investigate the potential value of UtA-PI, UA-PI, MCA-PI, mean arterial pressure (MAP) and serum levels of PlGF and sFlt-1, at 35-37 weeks' gestation, in the prediction of adverse perinatal outcomes, including development of PE, birth of an SGA neonate, Cesarean section for fetal distress before or during labor, umbilical arterial cord blood pH ≤ 7.0 or umbilical venous cord blood pH ≤ 7.1, 5-min Apgar score < 7 and NNU admission.
METHODS
The data for this study were derived from prospective screening for adverse obstetric outcomes in women attending for their routine hospital visit in the third trimester of pregnancy at King's College Hospital, London, and Medway Maritime Hospital, Gillingham, Kent, between February 2014 and December 2014. This visit, which is attended at 35 + 0 to 37 + 6 weeks' gestation, included the recording of maternal characteristics and medical history, estimation of fetal size from ultrasound measurement of fetal head circumference, abdominal circumference and femur length 13 , transabdominal Doppler assessment of the UtA-PI, UA-PI and fetal MCA-PI 14 -16 , measurement of MAP 17 and serum concentrations of PlGF and sFlt-1 (Cobas e411 system, Roche Diagnostics, Penzberg, Germany). Gestational age was determined by the measurement of fetal crown-rump length at 11-13 weeks or the fetal head circumference at 19-24 weeks 13, 18 . Written informed consent was obtained from the women agreeing to participate in a study on adverse pregnancy outcome, which was approved by the ethics committee of each participating hospital. The pregnancies included in the study were those with data available on all eight biomarkers and resulted in the live birth or stillbirth of a phenotypically normal baby at ≥ 24 weeks' gestation.
Patient characteristics
Patient characteristics that were recorded included maternal age, racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian and mixed), method of conception (spontaneous/use of ovulation drugs/in-vitro fertilization), cigarette smoking during pregnancy, medical history of chronic hypertension, diabetes mellitus, systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS) and parity (parous/nulliparous if no previous pregnancies ≥ 24 weeks). Maternal weight and height were also measured.
Outcome measures
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The outcome measures of the study were PE, SGA, Cesarean section for fetal distress before or during labor, umbilical arterial cord blood pH ≤ 7.0, umbilical venous cord blood pH ≤ 7.1, 5-min Apgar score < 7 and admission to NNU. The newborn was considered to be SGA if the birth weight was < 10 th percentile after correcting for gestational age at delivery 19 . The definition of PE was that of the International Society for the Study of Hypertension in Pregnancy 20 .
Statistical analysis
Comparison between the outcome groups was performed by chi-square test or Fisher's exact test for categorical variables and Mann-Whitney U-test for continuous variables. Categorical data are presented as n (%) and continuous data as median (interquartile range (IQR)).
The measured values of UtA-PI, UA-PI, MCA-PI, MAP, PlGF and sFlt-1 were expressed as multiples of the median (MoM) after adjustment for variables from maternal characteristics and medical history that affect these measurements 21 -25 . Univariable and multivariable logistic regression analyses were used to determine if log 10 MoM of each biomarker had a significant contribution in predicting each adverse outcome. The detection rate (DR) and false-positive rate (FPR) of screening were estimated for each adverse outcome. The performance of screening was determined by receiveroperating characteristics (ROC) curve analysis.
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 22.0; IBM Corp, Armonk, NY, USA) was used for the data analyses.
RESULTS

Study population
During the study period, 3953 women with a singleton pregnancy were examined and included in the analyses. The characteristics of the study population and the various subgroups according to adverse perinatal outcome are given in Table 1 .
Biomarkers in pregnancies with PE or birth of SGA neonate
For pregnancies resulting in PE or the birth of a SGA neonate, the median MoM values of each biomarker and the proportion of pregnancies with values above or below a cut-off percentile were compared to those of unaffected pregnancies with normal outcome (Table 2 ). Compared to the unaffected group, pregnancies that developed PE had significantly higher UtA-PI, MAP and serum sFlt-1 and lower serum PlGF (Table 2) . Multivariable logistic regression analysis demonstrated that significant Table 1 Maternal and pregnancy characteristics of study population of 3953 women with singleton pregnancy and those subgroups with adverse perinatal outcome of pre-eclampsia (PE), small-for-gestational-age (SGA) neonate, fetal distress before or during labor leading to Cesarean section, low umbilical arterial or venous cord blood pH, 5-min Apgar score < Data are given as median (interquartile range) or n (%). SGA defined as birth weight < 10 th percentile. Significant difference from cohort without adverse outcome adjusted for multiple comparisons with post-hoc Bonferroni correction: *P < 0.01; †P < 0.0001. EFW, estimated fetal weight; MAP, mean arterial pressure; MCA, middle cerebral artery; MoM, multiples of the median; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; UA, umbilical artery; UtA, uterine artery.
contributions to prediction of PE were provided by MAP, sFlt-1 and PlGF, (area under ROC curve (AUC), 0.913 (95% CI, 0.874-0.952)). The DR of combined screening by all significant contributors was 73.3%, at a FPR of 10% (Figure 1a) .
Compared to the unaffected group, pregnancies that delivered a SGA neonate had significantly higher UtA-PI, UA-PI and MAP and lower EFW and serum PlGF (Table 2) . Multivariable logistic regression analysis demonstrated that significant contributions to prediction of SGA were provided by EFW, PlGF and UtA-PI (AUC, 0.883 (95% CI, 0.867-0.899)). The DR of combined screening by all significant contributors was 62.8%, at a FPR of 10% (Figure 1a ).
Biomarkers in pregnancies with stillbirth
In the study population there was one stillbirth. The interval between assessment and delivery was 6 + 0 weeks. There were no risk factors noted in the maternal demographic characteristics as the pregnancy was in a nulliparous woman following a spontaneous conception, who was a non-smoker with a body mass index within normal range, no medical illness of note and no obstetric complications in the current pregnancy. The UtA-PI, MAP and serum sFlt-1 were < 95 th percentile and serum PlGF was > 5 th percentile. The estimated birth-weight Z-score was −2.4.
Biomarkers in pregnancies delivered by Cesarean section for fetal distress
In the 3952 pregnancies with live births, there were 3016 with vaginal delivery following spontaneous or induced labor, 436 with elective Cesarean section for a variety of indications and 500 with Cesarean section following spontaneous or induced labor; in the latter group the indication for Cesarean section was fetal distress in 275 cases. In the elective Cesarean-section group (n = 436) there were a variety of indications, including breech or transverse lie (n = 83), placenta previa (n = 22), previous Cesarean section, traumatic birth or maternal request (n = 291), maternal medical disorder (n = 33) and SGA fetuses with fetal compromise diagnosed by abnormal fetal heart rate patterns or fetal Doppler indices (n = 7).
For pregnancies resulting in delivery by Cesarean section for fetal distress, before labor (n = 7) or during labor (n = 275), the median MoM values of each biomarker and the proportion of pregnancies with values above or below a cut-off percentile were compared to those of pregnancies that delivered vaginally (Table 3) .
Compared to those that delivered vaginally, the group that underwent Cesarean section for fetal distress before labor showed significant alteration in all biomarkers (Table 3 ). In the study population for assessment of fetal distress during labor, the median interval from assessment to delivery was 4.0 (IQR, 3.0-4.7) weeks. Compared to those that delivered vaginally, the group with Cesarean section for fetal distress in labor showed higher EFW and serum sFlt-1, but no significant differences for the median MoM of the other biomarkers were seen. Multivariable logistic regression analysis demonstrated that significant contribution to prediction of Cesarean section for fetal distress was provided by EFW and sFlt-1 (AUC, 0.566 (95% CI, 0.531-0.601)). The DR was 15.3%, at a 10% FPR (Figure 1b) .
Biomarkers in pregnancies with adverse outcome after delivery
The median MoM values of biochemical and biophysical markers, and the proportion of pregnancies with values ) and during ( ) labor resulting in delivery by Cesarean section, using a combination of significant contributors from biophysical and biochemical markers at 35-37 weeks' gestation. Data are given as median (interquartile range) or n (%). Significant difference from cohort without adverse outcome adjusted for multiple comparisons with post-hoc Bonferroni correction: *P < 0.025; †P < 0.01; ‡P < 0.0001. EFW, estimated fetal weight; MAP, mean arterial pressure; MCA, middle cerebral artery; MoM, multiples of the median; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; UA, umbilical artery; UtA, uterine artery.
above or below a cut-off percentile, in pregnancies with and those without low cord blood pH, low 5-min Apgar score and NNU admission, are shown in Table 4 . No significant differences in the median MoM values of any of the biomarkers were found in the group with low cord blood pH compared to those with normal pH, in those with low 5-min Apgar score compared to those with normal score, and in those with NNU admission compared to those without admission.
DISCUSSION
Main findings of the study
The findings of this study demonstrate that, in pregnancies that develop PE and those that result in delivery of a SGA neonate, there is biophysical and biochemical evidence of impaired placentation or placental dysfunction reflected in increased UtA-PI, MAP and serum sFlt-1 and reduced serum PlGF. Screening by a combination of biomarkers at 36 weeks' gestation predicts the majority of pregnancies that develop PE and those that deliver SGA neonates. Impaired placentation/placental dysfunction and fetal hypoxemia are also observed in a small group of pregnancies with SGA fetuses delivering by elective Cesarean section for evidence of fetal distress. However, combined screening at 36 weeks is not useful in predicting fetal distress in labor necessitating delivery by Cesarean section, low cord blood pH, low Apgar score or NNU admission.
Strengths and limitations of the study
The strengths of this third-trimester screening study are, first, examination of pregnant women attending for routine care, second, use of a specific methodology and appropriately-trained doctors to measure MAP and carry out the Doppler studies, third, use of automated machines to obtain prospectively reproducible measurements of serum PlGF and sFlt-1, fourth, estimation of MoM values for biophysical and biochemical markers after adjustment for factors that affect the measurements, and fifth, examination of a wide range of well-accepted indicators of adverse perinatal outcome.
The main limitation of the study is that the results of the 35-37 weeks' scan were made available to the obstetricians of the patients who would have taken specific actions of further monitoring and delivery of the cases of suspected SGA with abnormal Doppler findings. It could therefore be argued that the performance of screening for adverse perinatal outcomes by biomarkers of impaired placentation and fetal hypoxemia would have been negatively biased. It is possible that some of the cases of SGA and fetal distress that were delivered by elective Cesarean section would have resulted in stillbirth or fetal distress in labor and low cord blood pH had they not been detected by the routine assessment at 36 weeks. However, the number of these cases was very small and it is therefore unlikely that they would have had a major impact on the overall effect of adverse events in labor and after birth.
Comparison with findings from previous studies
The results of this study are comparable to those of the only previous screening study that examined biomarkers of impaired placentation/placental dysfunction and fetal hypoxemia at 30-34 weeks' gestation and reported that these markers are useful in the prediction of PE and birth of SGA neonates, but not of adverse events in labor or after birth 11 .
Implications for clinical practice
An integrated clinical assessment at 36 weeks' gestation, which includes fetal biometry and measurement of biomarkers, identifies a high proportion of pregnancies that subsequently develop PE and those delivering SGA neonates. It was previously proposed that prediction of most cases of term PE and SGA is best achieved by a third-trimester assessment at around 36 weeks' gestation. It was also suggested that such timing of the assessment would inevitably miss the cases of preterm PE and SGA and it was therefore proposed that these cases should be identified at an integrated clinic at 22 weeks and receive close monitoring for early diagnosis of PE and/or SGA, and appropriate timing of delivery 3, 26 .
In pregnancies without SGA or PE, combined screening at 36 weeks is not useful in the prediction of adverse events during labor or after birth. It is possible that this finding is the consequence of the long delay of about 4 weeks between assessment and delivery or the effects of the events in labor and delivery on the outcome measures that overshadow the contribution of chronic hypoxia. Alternatively, this finding provides support for the hypothesis proposed more than 20 years ago, that impaired placentation or placental dysfunction is usually not severe enough to cause fetal hypoxia until reduced nutrition has stunted the size of the fetus sufficiently to become SGA; consequently, tests of fetal hypoxia would rarely be useful when the fetus is growing normally 12 . Research into the causes of morbidity in appropriately-grown fetuses should perhaps look for pathologies other than chronic fetal hypoxia.
